remune

a therapeutic vaccine developed by Jonas Salk; contains killed HIV stripped of its outer coating after which a chemical is added that helps immune cells recognize invaders and remember their shape

Networked: 20 relevant articles (1 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	QUEST Study Group: 2 articles (08/2005 - 09/2001)
2.	Chandeying, V: 2 articles (09/2004 - 09/2001)
3.	Churdboonchart, V: 2 articles (09/2004 - 09/2001)
4.	Kulpradist, S: 2 articles (09/2004 - 09/2001)
5.	Rugpao, S: 2 articles (09/2004 - 09/2001)
6.	Sirawaraporn, W: 2 articles (09/2004 - 09/2001)
7.	Sukeepaisarncharoen, W: 2 articles (09/2004 - 09/2001)
8.	Moss, R B: 2 articles (09/2001 - 05/2001)
9.	Bernard, Nicole F: 1 article (11/2006)
10.	Boisvert, Marie-Pierre: 1 article (11/2006)

Related Diseases

1.	Viremia 11/28/2006 - "This study explored whether HAART intensification with Remune vaccination before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART. " 09/01/2001 - "Participants with sustained viremia <50 copies/mL were randomized to one of three 5-month, double-blinded study treatment groups: HAART alone, HAART + ALVAC-HIV (vCP1452), or HAART + ALVAC-HIV (vCP1452) + Remune. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 05/21/1999 - "The study is a clinical-endpoint trial which looks for statistically significant differences in AIDS sickness or death between patients who add remune to their treatment regimens versus those who use a placebo. " 03/01/2002 - "In June 1998, Merrill Lynch had expected an FDA filing for Remune by the end of 1999, and in May 1999 Agouron was hoping to file an NDA for the use of Remune against AIDS during 2001. " 09/01/2004 - "Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand." 04/08/1996 - " Future clinical trials of HIV-infected individuals in Thailand may include a 2000-person clinical endpoint trial to determine the effectiveness of Remune in delaying the progression of HIV infection to AIDS, and an open-label safety trial involving up to 7700 individuals." 07/10/1998 - "At the 12th World AIDS Conference, New York University immunologist Dr. Fred Valentine described impressive results of a multicenter controlled trial of remune, a vaccine developed by Salk. "
3.	Infections 01/01/1998 - "These data suggest that REMUNE is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE to treat HIV-1 infection." 09/01/2001 - "These results suggest that long-term treatment of HIV-1 infection with Remune monotherapy is safe and results in a stabilization of CD4+ counts. " 09/01/2001 - "The purpose of this 2-year follow-up study was to investigate the long-term effect of Remune as monotherapy for HIV-1 infection. " 07/10/1998 - "Remune works by stimulating the lymphoproliferative response (LPR), which is the ability of certain cells to recognize a virus and rapidly produce other cells to combat the infection. " 05/01/2001 - "We examined HIV-1 antigen specific intracellular expression of perforin on CD4+ and CD8+ lymphocytes in subjects with chronic HIV-1 infection on antiviral drug therapy after immunization with a gp120-depleted, whole killed HIV-1 immunogen (inactivated, gp120-depleted HIV-1 in IFA, REMUNE). "
4.	Disease Progression 09/01/2004 - "To observe the long-term effects of an immune-based therapy HIV-1 Immunogen (REMUNE; Immune Response Corp., Carlsbad, CA, USA) as a first course of treatment designed to sustain the immune system and thus delay the initiation of therapy with antiretroviral drugs and/or delay disease progression. " 05/01/1998 - "Developed by Dr. Jonas Salk, researchers hope Remune's actions can alter the course of HIV infection and slow disease progression. " 09/01/2004 - "In this open-label, multi-institute extended phase II P2101B study, disease progression, CD4 and CD8 T-cell counts, HIV-1 RNA levels, and genotypic antiretroviral drug resistance were examined in 223 asymptomatic HIV-1-infected Thai volunteers receiving REMUNE every 12 weeks over 132 weeks. " 09/01/2004 - "Patients treated with REMUNE demonstrated a low rate of clinical disease progression (0.72 per 100 person-years), higher CD4 and CD8 T-cell counts, higher body weight before and after treatment in the same patient, and stable viral load with no serious adverse events. " 05/01/1996 - "A clinical trial to test an immune therapy developed by polio pioneer Jonas Salk has begun enrollment of 3,000 participants, who will receive Remune shots every 12 weeks for 3 years to see if disease progression is slowed. "
5.	HIV Infections (HIV Infection) 01/01/1998 - "The safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. " 04/08/1996 - " Future clinical trials of HIV-infected individuals in Thailand may include a 2000-person clinical endpoint trial to determine the effectiveness of Remune in delaying the progression of HIV infection to AIDS, and an open-label safety trial involving up to 7700 individuals." 05/01/1998 - "Developed by Dr. Jonas Salk, researchers hope Remune's actions can alter the course of HIV infection and slow disease progression. " 12/01/2003 - "The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection." 11/01/1998 - "However, since remune is a therapeutic vaccine, it cannot prevent HIV infection. "

Related Drugs and Biologics

1.	Vaccines
2.	RNA (Ribonucleic Acid)
3.	ALVAC-HIV vCP1452
4.	Antigens
5.	incomplete Freund's adjuvant
6.	AIDSVAX
7.	Perforin
8.	CC Chemokines
9.	AIDS Vaccines
10.	Cytokines

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Therapeutics
3.	Aftercare (After-Treatment)